BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28195507)

  • 1. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.
    Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Nakayama H; Sakurada A; Sugahara S; Koizumi K; Tokuuye K
    Br J Radiol; 2017 May; 90(1073):20160508. PubMed ID: 28195507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
    Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
    Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
    Yamaguchi S; Ohguri T; Ide S; Aoki T; Imada H; Yahara K; Narisada H; Korogi Y
    Lung Cancer; 2013 Nov; 82(2):260-5. PubMed ID: 24054547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
    Takeda A; Ohashi T; Kunieda E; Sanuki N; Enomoto T; Takeda T; Oku Y; Shigematsu N
    Br J Radiol; 2012 May; 85(1013):636-42. PubMed ID: 22253343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
    Glick D; Lyen S; Kandel S; Shapera S; Le LW; Lindsay P; Wong O; Bezjak A; Brade A; Cho BCJ; Hope A; Sun A; Giuliani M
    Clin Lung Cancer; 2018 Mar; 19(2):e219-e226. PubMed ID: 29066051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
    Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
    Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
    Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
    Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.
    Li F; Liu H; Wu H; Liang S; Xu Y
    Radiat Oncol; 2021 Apr; 16(1):70. PubMed ID: 33849579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
    Harder EM; Park HS; Chen ZJ; Decker RH
    Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
    Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
    Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
    Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
    Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
    Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
    Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
    Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
    Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.
    Yamashita H; Nakagawa K; Nakamura N; Koyanagi H; Tago M; Igaki H; Shiraishi K; Sasano N; Ohtomo K
    Radiat Oncol; 2007 Jun; 2():21. PubMed ID: 17553175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
    Ueki N; Matsuo Y; Togashi Y; Kubo T; Shibuya K; Iizuka Y; Mizowaki T; Togashi K; Mishima M; Hiraoka M
    J Thorac Oncol; 2015 Jan; 10(1):116-25. PubMed ID: 25376512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
    Takeda A; Ohashi T; Kunieda E; Enomoto T; Sanuki N; Takeda T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):685-90. PubMed ID: 20510193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.